|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sridhar SS, Freedland SJ, Gleave ME,
Higano C, Mulders P, Parker C, Sartor O and Saad F:
Castration-resistant prostate cancer: From new pathophysiology to
new treatment. Eur Urol. 65:289–299. 2014. View Article : Google Scholar
|
|
3
|
Sturge J, Caley MP and Waxman J: Bone
metastasis in prostate cancer: Emerging therapeutic strategies. Nat
Rev Clin Oncol. 8:357–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Wang Z and Gemeinhart RA:
Progress in microRNA delivery. J Control Release. 172:962–974.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: Past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goto Y, Kojima S, Nishikawa R, Kurozumi A,
Kato M, Enokida H, Matsushita R, Yamazaki K, Ishida Y, Nakagawa M,
et al: MicroRNA expression signature of castration-resistant
prostate cancer: The microRNA-221/222 cluster functions as a tumour
suppressor and disease progression marker. Br J Cancer.
113:1055–1065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okato A, Goto Y, Kurozumi A, Kato M,
Kojima S, Matsushita R, Yonemori M, Miyamoto K, Ichikawa T and Seki
N: Direct regulation of LAMP1 by tumor-suppressive microRNA-320a in
prostate cancer. Int J Oncol. 49:111–122. 2016.PubMed/NCBI
|
|
11
|
Gregory RI, Chendrimada TP, Cooch N and
Shiekhattar R: Human RISC couples microRNA biogenesis and
posttranscriptional gene silencing. Cell. 123:631–640. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chendrimada TP, Gregory RI, Kumaraswamy E,
Norman J, Cooch N, Nishikura K and Shiekhattar R: TRBP recruits the
Dicer complex to Ago2 for microRNA processing and gene silencing.
Nature. 436:740–744. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hutvágner G and Zamore PD: A microRNA in a
multiple-turnover RNAi enzyme complex. Science. 297:2056–2060.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matranga C, Tomari Y, Shin C, Bartel DP
and Zamore PD: Passenger-strand cleavage facilitates assembly of
siRNA into Ago2-containing RNAi enzyme complexes. Cell.
123:607–620. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; Chichester: 2009
|
|
16
|
Mataki H, Seki N, Mizuno K, Nohata N,
Kamikawaji K, Kumamoto T, Koshizuka K, Goto Y and Inoue H:
Dual-strand tumor-suppressor microRNA-145 (miR-145-5p and
miR-145-3p) coordinately targeted MTDH in lung squamous cell
carcinoma. Oncotarget. 7:72084–72098. 2016.PubMed/NCBI
|
|
17
|
Yonemori M, Seki N, Yoshino H, Matsushita
R, Miyamoto K, Nakagawa M and Enokida H: Dual tumor-suppressors
miR-139-5p and miR-139-3p targeting matrix metalloprotease 11 in
bladder cancer. Cancer Sci. 107:1233–1242. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kurozumi A, Goto Y, Matsushita R, Fukumoto
I, Kato M, Nishikawa R, Sakamoto S, Enokida H, Nakagawa M, Ichikawa
T, et al: Tumor-suppressive microRNA-223 inhibits cancer cell
migration and invasion by targeting ITGA3/ITGB1 signaling in
prostate cancer. Cancer Sci. 107:84–94. 2016. View Article : Google Scholar
|
|
19
|
Semenas J, Allegrucci C, Boorjian SA,
Mongan NP and Persson JL: Overcoming drug resistance and treating
advanced prostate cancer. Curr Drug Targets. 13:1308–1323. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fuse M, Kojima S, Enokida H, Chiyomaru T,
Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M,
et al: Tumor suppressive microRNAs (miR-222 and miR-31) regulate
molecular pathways based on microRNA expression signature in
prostate cancer. J Hum Genet. 57:691–699. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Goto Y, Kurozumi A, Enokida H, Ichikawa T
and Seki N: Functional significance of aberrantly expressed
microRNAs in prostate cancer. Int J Urol. 22:242–252. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kato M, Kurozumi A, Goto Y, Matsushita R,
Okato A, Nishikawa R, Fukumoto I, Koshizuka K, Ichikawa T and Seki
N: Regulation of metastasis-promoting LOXL2 gene expression by
antitumor microRNAs in prostate cancer. J Hum Genet. 62:123–132.
2017. View Article : Google Scholar
|
|
24
|
Abe F, Kitadate A, Ikeda S, Yamashita J,
Nakanishi H, Takahashi N, Asaka C, Teshima K, Miyagaki T, Sugaya M,
et al: Histone deacetylase inhibitors inhibit metastasis by
restoring a tumor suppressive microRNA-150 in advanced cutaneous
T-cell lymphoma. Oncotarget. 8:7572–7585. 2017.
|
|
25
|
Srivastava SK, Bhardwaj A, Singh S, Arora
S, Wang B, Grizzle WE and Singh AP: MicroRNA-150 directly targets
MUC4 and suppresses growth and malignant behavior of pancreatic
cancer cells. Carcinogenesis. 32:1832–1839. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qu Y, Pan S, Kang M, Dong R and Zhao J:
MicroRNA-150 functions as a tumor suppressor in osteosarcoma by
targeting IGF2BP1. Tumour Biol. 37:5275–5284. 2016. View Article : Google Scholar
|
|
27
|
Matsushita R, Yoshino H, Enokida H, Goto
Y, Miyamoto K, Yonemori M, Inoguchi S, Nakagawa M and Seki N:
Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145
(miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell
aggressiveness. Oncotarget. 7:28460–28487. 2016.PubMed/NCBI
|
|
28
|
Bradshaw AD: Diverse biological functions
of the SPARC family of proteins. Int J Biochem Cell Biol.
44:480–488. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu
JL, Li Y, Yuan YF and Guan XY: SPOCK1 is regulated by CHD1L and
blocks apoptosis and promotes HCC cell invasiveness and metastasis
in mice. Gastroenterology. 144:179–191.e4. 2013. View Article : Google Scholar
|
|
30
|
Ma LJ, Wu WJ, Wang YH, Wu TF, Liang PI,
Chang IW, He HL and Li CF: SPOCK1 Overexpression confers a poor
prognosis in urothelial carcinoma. J Cancer. 7:467–476. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: SPOCK1 as a potential
cancer prognostic marker promotes the proliferation and metastasis
of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol
Cancer. 14:122015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kusakabe M, Kutomi T, Watanabe K, Emoto N,
Aki N, Kage H, Hamano E, Kitagawa H, Nagase T, Sano A, et al:
Identification of G0S2 as a gene frequently methylated in squamous
lung cancer by combination of in silico and experimental
approaches. Int J Cancer. 126:1895–1902. 2010.
|
|
33
|
Miao L, Wang Y, Xia H, Yao C, Cai H and
Song Y: SPOCK1 is a novel transforming growth factor-β target gene
that regulates lung cancer cell epithelial-mesenchymal transition.
Biochem Biophys Res Commun. 440:792–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim HP, Han SW, Song SH, Jeong EG, Lee MY,
Hwang D, Im SA, Bang YJ and Kim TY: Testican-1-mediated
epithelial-mesenchymal transition signaling confers acquired
resistance to lapatinib in HER2-positive gastric cancer. Oncogene.
33:3334–3341. 2014. View Article : Google Scholar
|
|
35
|
Uramoto H, Iwata T, Onitsuka T, Shimokawa
H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in
EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res.
30:2513–2517. 2010.PubMed/NCBI
|
|
36
|
Choe C, Shin YS, Kim C, Choi SJ, Lee J,
Kim SY, Cho YB and Kim J: Crosstalk with cancer-associated
fibroblasts induces resistance of non-small cell lung cancer cells
to epidermal growth factor receptor tyrosine kinase inhibition.
Onco Targets Ther. 8:3665–3678. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Crawford ED, Higano CS, Shore ND, Hussain
M and Petrylak DP: Treating patients with metastatic castration
resistant prostate xancer: A comprehensive review of available
therapies. J Urol. 194:1537–1547. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Martin SK, Pu H, Penticuff JC, Cao Z,
Horbinski C and Kyprianou N: Multinucleation and
mesenchymal-to-epithelial transition alleviate resistance to
combined cabazitaxel and anti-androgen therapy in advanced prostate
cancer. Cancer Res. 76:912–926. 2016. View Article : Google Scholar
|
|
39
|
Nakazawa M and Kyprianou N:
Epithelial-mesenchymal-transition regulators in prostate cancer:
Androgens and beyond. J Steroid Biochem Mol Biol. 166:84–90. 2017.
View Article : Google Scholar
|
|
40
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Haider M, Zhang X, Coleman I, Ericson N,
True LD, Lam HM, Brown LG, Ketchanji M, Nghiem B, Lakely B, et al:
Epithelial mesenchymal-like transition occurs in a subset of cells
in castration resistant prostate cancer bone metastases. Clin Exp
Metastasis. 33:239–248. 2016. View Article : Google Scholar :
|
|
42
|
Chen Q, Yao YT, Xu H, Chen YB, Gu M, Cai
ZK and Wang Z: SPOCK1 promotes tumor growth and metastasis in human
prostate cancer. Drug Des Devel Ther. 10:2311–2321. 2016.
View Article : Google Scholar : PubMed/NCBI
|
